Helen Sabzevari, PhD, President and CEO of Precigen, discusses the barriers to implementing cell and gene therapies that impede the accessibility and implementation of these precision medicines. Dr. Sabzevari also explains how key cell and gene therapy platforms and tools can provide safety measures, such as guardrails to cellular toxicity, and address cost by offering “off-the-shelf” efficient gene delivery vectors that can be used on-site, cutting out centralized manufacturing.

Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.

Produced by Bill Levine

Hosted by Jonathan D. Grinstein, PhD

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack

Hosted on Acast. See acast.com/privacy for more information.

Luca Quagliata, PhD, global head of medical affairs for clinical NGS and oncology at Thermo Fisher Scientific, shares how his career has been intertwined with precision medicine, beginning with his time as a student in Italy during the early 2000s. Quagliata examines the significance of genomic profiling within the cancer care continuum, outlining the essential steps and touchpoints necessary to ensure the accessibility of personalized oncology treatment for all individuals.

Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.

7Q4XKpRvPIvPZPkK6RbZ

Produced by Bill Levine

Hosted by Jonathan D. Grinstein, PhD

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack

Hosted on Acast. See acast.com/privacy for more information.

In the premiere episode of Behind the Breakthroughs, Geoff Oxnard, MD, VP of Clinical Development at Lilly and a Thoracic Oncologist at Boston Medical Center, shares his journey in precision medicine, beginning with his introduction to genetic testing as a Medical Oncology Fellow at Memorial Sloan-Kettering Cancer Center and as an academic researcher. Oxnard discusses how differences in impact and reach influenced his decision to move from academia to industry. He also explains how the adoption of precision testing in the United States is influenced by perspective rather than accessibility. This episode also covers flexible enrollment in clinical trials, adapting to patient perspectives on clinical research as care, the current state of precision medicine, particularly precision oncology, in the United States and elsewhere, and more.

Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.

Produced by Bill Levine

Hosted by Jonathan D. Grinstein, PhD

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack

Hosted on Acast. See acast.com/privacy for more information.